Convergence and divergence of genetic and modular networks between diabetes and breast cancer

Xiaoxu Zhang a, Yingying Zhang a, Yanan Yu a, Jun Liu a, Ye Yuan b, Yijun Zhao c, Haixia Li d, Jie Wang d, Zhong Wang a, *

a Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China
b Nanjing University of Chinese Medicine, Nanjing, China
c China Academy of Chinese Medical Sciences, Beijing, China
d Department of Cardiology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Xicheng District, Beijing, China

Received: August 20, 2014; Accepted: October 22, 2014

Abstract
Diabetes mellitus (DM) and breast cancer (BC) can simultaneously occur in the same patient populations, but the molecular relationship between them remains unknown. In this study, we constructed genetic networks and used modularized analysis approaches to investigate the multi-dimensional characteristics of two diseases and one disease subtype. A text search engine (Agilent Literature Search 2.71) and MCODE software were applied to validate potential subnetworks and to divide the modules, respectively. A total of 793 DM-related genes, 386 type 2 diabetes (T2DM) genes and 873 BC-related genes were identified from the Online Mendelian Inheritance in Man database. For DM and BC, a total of 99 overlapping genes, 9 modules, 29 biological processes and 7 pathways were identified. Meanwhile, for T2DM and BC, 56 overlapping genes, 5 modules, 20 biological processes and 12 pathways were identified. Based on the Gene Ontology functional enrichment analysis of the top 10 non-overlapping modules of the two diseases, 10 biological functions and 5 pathways overlapped between them. The glycosphingolipid and lysosome pathways verified molecular mechanisms of cell death related to both DM and BC. We also identified new biological functions of dopamine receptors and four signalling pathways (Parkinson’s disease, Alzheimer’s disease, Huntington’s disease and long-term depression) related to both diseases; these warrant further investigation. Our results illustrate the landscape of the novel molecular substructures between DM and BC, which may support a new model for complex disease classification and rational therapies for multiple diseases.

Keywords: breast cancer ● diabetes ● type 2 diabetes ● gene interaction network ● modularized analysis

Introduction
Diabetes mellitus (DM) and breast cancer (BC) are common diseases with high morbidity that are increasingly recognized to occur in the same patient populations. Researchers have noted common factors between the two diseases, including factors related to pathological processes, such as family history, obesity and alcohol intake [1, 2]. In the current study, we have also identified intersection points during pathogenesis and in pathologic mechanisms and pharmacokinetics. One meta-analysis has suggested that women with type 2 diabetes (T2DM) might be at increased risk of BC [3]. Meanwhile, the analysis of population-based medical records in Ontario, Canada, has indicated that postmenopausal women with BC are more likely to develop DM than women without BC [4]. The increased weight gain of adjuvant chemotherapy or oestrogen suppression may further promote diabetes [5]. A high body mass index (BMI) is a risk factor for insulin resistance [3]. In post-menopausal populations, obesity has been established as a risk factor for BC [6, 7]. A study showed that insulin has the ability to stimulate aromatase activity further increasing the levels of bioavailable estradiol, which suggested that insulin could also have indirect effects on BC progression [8]. Insulin resistance predisposes DM and insulin resistance of type 2 diabetes lead to the increased risk of BC [9].
Researchers have attempted to determine the mechanisms related to these associations. Oxidative stress and inflammatory state associated with an increase in bodyweight are common to both T2DM and BC [1], and some studies have focused on the relationship between T2DM and BC [10, 11]. A study hypothesized three mechanisms that were the relationship between DM and BC including activation of the insulin-like-growth-factor pathway, activation of the insulin pathway and regulation of endogenous sex hormones [12]. However, the molecular mechanisms between the two diseases still need to further explore from the system aspect. In this study, we created a modular network representation of T2DM, a subtype of DM, to explore the relationship between DM (and T2DM) and BC at the molecular level and we made detailed observations of the common features of these two diseases.

Despite the numerous treatment options for diabetes, individualized long-term treatment remains challenging in many cases [13, 14]. For BC, the understanding of its initiation and progression, as well as its identification, also remain challenging [15, 16].

Gene-based network analysis is a promising method for systems biology studies that takes full advantage of large online databases. This approach can be used to map genes, pathways and diseases into networks showing activation, inhibition and combinations of connections [17]. Recent evidence has indicated that modular structures may exist in biological systematic networks [18], and researchers continue to study the correlations among diseases from the perspective of the network module [19].

Therefore, in this study, we used target genes to construct a pathological molecular network to explore the complicated relationships between DM (T2DM) and BC, and we aimed to reveal their relationship from the perspective of a system network module.

Materials and methods

Network construction and analysis

Genes related to BC and diabetes were derived from Online Mendelian Inheritance in Man (OMIM), a database of human genes and genetic disorders. The results were entered into the Agilent Literature Search

Fig. 1 Module networks for BC, DM and T2DM. (A) The 56 overlapping genes among BC, DM and T2DM. (B) BC-, DM- and T2DM-related module networks. (C) The three overlapping modules among BC, DM and T2DM.
software v. 2.71, which was used to construct a network representation of gene/protein associations. Finally, Cytoscape software was used to visualize this network and to analyse the topology of this network. For instance, network parameters such as clustering coefficient, network diameter, network centralization and network radius were calculated and illustrated.

**Identification of modules**

We used MCODE, a clustering algorithm-based software, as a discovery tool in network module division, and the results were visualized using
Cytoscape software (parameters: connectivity threshold = 2, core threshold K = 2 and node score threshold = 0.2).

Functional enrichment analysis

Hypergeometric distribution tests were performed to analyse the function of the modules using DAVID software (http://david.abcc.ncifcrf.gov/) (parameters: count = 2, EASE = 0.01, species and background = Homo sapiens). Using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) annotation, the biological processes and KEGG pathway corresponding to the modules were identified, and the P values were ranked.

Results

DM- and BC-related genes in the OMIM database

Our search of the OMIM database revealed 793 DM-related, 386 T2DM and 873 BC-related genes (Table S1). A total of 56 overlapping genes were detected between the three diseases, and these overlapping genes accounted for 7.06% (56/793) of the known DM-related genes, 14.51% (56/386) of T2DM-related genes and 6.41% (56/873) of BC-related genes (Fig. 1A).

Disease network property analysis

Using Agilent Literature Search v. 2.71 software, respective networks were created. The network for DM-related genes included 2654 nodes (genes) and 10,104 edges (interactions). The network for T2DM-related genes included 1613 nodes (genes) and 5181 edges (interactions), and the network for BC-related genes included 3540 nodes (genes) and 16,545 edges (interactions; Fig. 2A, C and E). The topological attributes and modularity of the networks for these three networks are listed in Table 1. Similar distributions of node degree that followed the power-law distribution appeared in all of the networks. The three gene interaction networks were scale-free networks (Fig. 2B, D and F).

Modularity analysis

Entering these results into MCODE v1.13 software yielded 170, 154 modules from the BC network, 110 modules from the DM network and 110 modules from the T2DM network (Fig. 1B and C). Nine overlapping modules were identified between DM and BC. Mb11.d12.d211, Mb26.d32, Mb52.d50, Mb67.d67, Mb105.d89, Mb138.d107, Mb153.d141, Mb157.d147 and Mb159.d146. Five overlapping modules were identified between T2DM and BC: Mb8.2d8, Mb11.d12.d211, Mb105.d89, Mb139.2d78, and Mb153.d141, Mb157.d147 and Mb159.d146. Twenty overlapping modules were identified between DM and T2DM: Mb1.d5, Mb2.d16, Mb2.d17, Mb2.d20, Mb3.d20, Mb7.d17, Mb11.d12.d211, Mb139.d278 and Mb153.d141, Mb157.d147 and Mb159.d146. Forty overlapping modules were identified between DM and T2DM: Mb2.d5, Mb2.d16, Mb2.d17, Mb2.d20, Mb3.d20, Mb7.d17, Mb11.d12.d211, Mb139.d278 and Mb153.d141, Mb157.d147 and Mb159.d146. The first ten non-overlapping modules of the BC, DM and T2DM networks sorted by MCODE score are shown in Figure 3A.

Functional enrichment analysis

Common modules between BC and DM

The BC and DM networks shared 9 overlapping modules (Fig. 4A) with 29 biological functional annotations (Fig. 4B), including 7 for response processes, 6 for metabolic processes, 5 for biosynthesis, 4 for glycosylation and 2 each for oxidation, autophagy, development processes, pathways, transport processes and phosphorylation. Seven pathways were identified, including 1 each for disease-related, biosynthesis, lysosome and phosphorylation pathways (Fig. 4C).

Table 1 Comparison of the network topological attributes and modularity of the BC-, DM- and T2DM-related networks

|                     | DM  | BC  | T2DM |
|---------------------|-----|-----|------|
| Clustering coefficient | 0.591 | 0.569 | 0.603 |
| Network diameter     | 11  | 10  | 11   |
| Network radius       | 1   | 1   | 1    |
| Network centralization | 0.061 | 0.079 | 0.051 |
| No. of nodes         | 2654| 3540| 1613 |
| Edges                | 10104| 16545| 5181 |
| Genes                | 793 | 873 | 386  |
| Percentage of overlapping genes to total value | 7.06% (56/793) | 6.41% (56/873) | 14.51% (56/386) |
| Clusters             | 154 | 170 | 110  |
| Average size         | 9.221| 11.035| 7.536 |
| Maximum size         | 133 | 227 | 95   |
| Minimum size         | 3   | 3   | 3    |
| Modularity           | 0.323| 0.291| 0.385 |
| Percentage of overlapping module of total module value | 1.94% (3/154) | 1.76% (3/170) | 2.72% (3/110) |

© 2015 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
Common modules between BC and T2DM networks

The BC and T2DM networks shared 5 overlapping modules (Fig. 6A) with 20 biological functional annotations (Fig. 6B), including 8 for metabolic processes, 5 for biosynthesis and 1 each for glycosylation, autophagy, response processes regulation of hormone levels. Twelve common pathways were identified (Fig. 6C), including 8 for metabolic processes, 2 for biosynthesis and 1 each for lysosomes and interconversions.

Unique modules for different diseases

On the basis of the GO functional enrichment analysis of the top 10 non-overlapping modules of the two diseases, as sorted by MCODE score, we identified 335 GO biological annotations and 23 pathways from modules in the DM network; 620 GO biological annotations and 61 pathways from modules in the BC network; and 114 GO biological annotations and 9 pathways from modules in the T2DM network (Fig. 3B and C). The top 10 non-overlapping modules according to specific functional enrichment analysis are listed in Table S2.
Fig. 4 (A) BC and DM shared 9 overlapping modules. (B) Biological functions of BC and DM shared 9 overlapping modules. (C) Pathways of BC and DM shared 9 overlapping modules. (D) BC, DM and T2DM shared 3 overlapping modules. (E) Biological functions of BC, DM and T2DM shared 3 overlapping modules. (F) Pathways of BC, DM and T2DM shared 3 overlapping modules.

Fig. 5 Overview of the Lysosome pathway. The module appears in this pathway marked with a red frame.
Discussion

Many common biological backgrounds between DM and BC were revealed in our study. DM and BC share 99 overlapping genes that may be responsible for the genetic similarity of the two diseases. For example, insulin-like growth factor (IGF) 1R overexpression is associated with DM development [20]. Hyperglycaemia promotes BC development by altering IGF1R [21]. After a diagnosis of BC, women with the BRCA2 mutation face a 2-fold increase in the risk of DM, which is exacerbated by a high BMI [22]. A previous study indicated that women who carry BRCA2 mutations have a substantially increased risk of developing BC and DM [22, 23]. The 56 overlapping genes indicate a certain degree of genetic similarity among BC, DM and T2DM. For example, BRCA2, CYP19A1, IGF1, IGF1R, FANCA and HNF1A have been identified as biomarkers or therapeutic targets of the two diseases based on direct evidence from the Comparative Toxicogenomics Database (http://cdiabetesbase.org/).

Previous studies have demonstrated that glycation and oxidation of High Density Lipoprotein in diabetic patients could lead to abnormal actions on MDA-MB-231 cell proliferation, migration and invasion, thereby promoting the progression of BC [10]. Individuals with obesity, the metabolic syndrome and T2DM have increased BC incidence and mortality [24–26]. Additionally, phosphoinositide phosphatases are implicated in a large and diverse array of human diseases, including cancer and diabetes [27]. Observational studies have shown that the daily use of metformin in BC patients imparts a survival benefit and a higher pathologic complete response after neoadjuvant chemotherapy [28, 29]. One meta-analysis has suggested that metformin is associated with a reduced risk of cancer in diabetic patients [30]. In addition, impaired autophagy has been associated with the pathogenesis of BC and diabetes [31]. Furthermore, otelixizumab, a chimeric CD3 antibody, has been genetically engineered to remove the glycosylation site in the Fc domain to treat diabetes [32]. This body of research further confirms correlations between DM and BC.

In this study, DM and BC were found to share two overlapping pathways: GSL and lysosome biosynthesis. GSLs might have an effect on signal transduction related to insulin receptors and on epithelial growth factors that are important for diabetes [33]. GSLs are especially concentrated in plasma membrane lipid domains that are specialized for cell signalling. Plasma membranes have typical structures called rafts and caveola domain structures, with large amounts of sphingolipids, cholesterol and sphingomyelin [33]. Sphingolipids exert biological effects through cellular proliferation, differentiation and cell death, and they interact with several pathways involved in insulin resistance, oxidative stress, inflammation and apoptosis, all of which are linked to T2DM [34–36]. Studies have illustrated aberrant glycosylation in BC cells, and glycosylation changes are associated with GSLs [37, 38]. Ceramide glycosylation, which is overexpressed in metastatic breast tumours controlling GSL synthesis, plays a role in modulating BC stem cells [39–41]. BC cells affect proteins made downstream of lysosomal production, activating cell death [42]. Insulin-like growth factors play a critical role in BC, i.e. down-regulation via a lysosome-dependent pathway [43–45]. Autophagosomes are responsible for cell death and delivering extra proteins to lysosomes for recycling in the pathogenesis of cancer and diabetes. [46]. Thus, two common pathways are implicated in the cell death mechanism of these two linked diseases [47, 48]. Our analysis of the non-overlapping network, modules revealed common biological processes related to the two diseases, for example, pathogenesis of metabolic processes [49–51]. In contrast, the non-overlapping modules are related to some unique biological processes related to the specific disease. For example, a study found that patients with
DM may develop corneal complications and delayed wound healing [52]. Chromosome localization as a biological process has been associated with risk of BC in a recent genome-wide association study of women of European ancestry [53]. These non-intersecting biological processes further validate the feasibility of modularized network analysis approaches.

The construction of molecular networks and the function of the module annotation enable us to systematically scan the overall picture and the details of these two linked diseases. Using system analysis, we found that some new overlapping biological processes and signalling pathways, for example, the dopamine receptor signalling pathway and Parkinson’s disease, Alzheimer’s disease, Huntington’s disease and long-term depression. Modularized network analyses provide us with new knowledge and direction for future studies. Of course, real-time updating of online databases requires that we update our analyses as these databases expand in the future.

Conclusion

The overlapping modules of function annotation between DM and BC were investigated in this study. Based on overlapping genes, network modules were established to identify common pathogeneses between DM and BC. In addition to our gene analysis, a large body of literature was reviewed to validate the dependent and independent risk factors that co-exist between BC and DM. We also identified some new biological functions and signalling pathways related to the two diseases that need to be explored further, for example, dopamine receptor biological functions and Parkinson’s disease, Alzheimer’s disease, Huntington’s disease and long-term depression. Our study illuminates the landscape of the genetic relationship between DM and BC, which may provide a new foundation for drug development and clinical medicine.

Conflicts of interest

The authors declare no conflict of interest.

Supporting information

Additional Supporting Information may be found in the online version of this article:

Data S1 DM- and BC-related genes in the OMIM database.

References

1. Crujeiras AB, Diaz-Lagares A, Carreira MC, et al. Oxidative stress associated to dysfunctional adipose tissue: a potential link between obesity, type 2 diabetes mellitus and breast cancer. Free Radic Res. 2013; 47: 243–56.
2. Hankinson SE, Colditz GA, Willett WC. Towards an integrated model for breast cancer etiology: the lifelong interplay of genes, lifestyle, and hormones. Breast Cancer Res. 2004; 6: 213–8.
3. Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer; 2007; 121: 856–62.
4. Lipscombe LL, Chan WW, Yun L, et al. Incidence of diabetes among postmenopausal breast cancer survivors. Diabetologia. 2013; 56: 476–83.
5. Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab. 2003; 88: 2404–11.
6. Carmichael AR. Obesity as a risk factor for development and poor prognosis of breast cancer. BJOG 2006; 10: 1160–6.
7. Cleary MP, Mahile NJ. The role of body mass index in the relative risk of developing premenopausal versus postmenopausal breast cancer. Proc Soc Exp Biol Med. 1997; 216: 28–43.
8. McTernan PG, Anwar A, Eggo MC, et al. Gender differences in the regulation of P450 aromatase expression and activity in human adipose tissue. Int J Obes. 2000; 24: 875–81.
9. Lann D, LeRoith D. The role of endocrine insulin-like growth factor-1 and insulin in breast cancer. J Mammary Gland Biol Neoplasia. 2008; 13: 371–9.
10. Pan B, Ren H, Ma Y, et al. High-density lipoprotein of patients with type 2 diabetes mellitus elevates the capability of promoting migration and invasion of breast cancer cells. Int J Cancer. 2012; 131: 70–82.
11. Ahmadieh H, Azar ST. Type 2 diabetes mellitus, oral diabetic medications, insulin therapy, and overall breast cancer risk. ISRN Endocrinol. 2013; 2013: 181240.
12. Wolf I, Sadetzki S, Catane R, et al. Diabetes mellitus and breast cancer. Lancet Oncol. 2005; 6: 103–11.
13. Malandrino N, Smith RJ. Personalized medicine in diabetes. Clin Chem. 2011; 57: 231–40.
14. Fei BB, Ling L, Hua C, et al. Effects of soybean oligosaccharides on antioxidant enzyme activities and insulin resistance in pregnant women with gestational diabetes mellitus. Food Chem. 2014; 158: 429–32.
15. Bhattacharya S, Frangioni JV, Hoffman RM, et al. The challenges posed by cancer heterogeneity. Nat Biotechnol. 2012; 30: 604–10.
16. Nandy A, Gangopadhyay S, Mukhopadhyay A. Individualizing breast cancer treatment—The dawn of personalized medicine. Exp Cell Res. 2014; 320: 1–11.
17. Csermely P, Korcsmaros T, Kiss HJ, et al. Structure and dynamics of molecular networks: a novel paradigm of drug discovery: a comprehensive review. Pharmacol Ther. 2013; 138: 333–408.
18. Lorenz DM, Bengen T, Deen MW. The emergence of modularity in biological systems. Phys Life Rev. 2011; 8: 129–60.
19. Zhang Y, Kong P, Chen Y, et al. Significant overlapping modules and biological processes between stroke and coronary heart disease. CNS Neurol Drug Disc Targets. 2014; 13: 652–60.
20. van Dijk PR, Logtenberg SJ, Greener KH, et al. Effect of i.p. insulin administration on IGFI and IGFBP1 in type 1 diabetes. Endocr Connect. 2014; 3: 17–23.
21. Lopez R, Arumugam A, Joseph R, et al. Hyperglycemia enhances the proliferation of non-tumorigenic and malignant mammary epithelial cells through increased leptin/IGF1R signaling and activation of AKT/mTOR. PLoS ONE. 2013; 8: e79708.
22. Bordeleau L, Lipscombe L, Lubinski J, et al. Diabetes and breast cancer among women with BRCA1 and BRCA2 mutations. Cancer. 2011; 117: 1812–8.
23. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history; a combined analysis of 22 studies. Am J Hum Genet. 2003; 72: 1117–30.

24. Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003; 348: 1625–38.

25. Campbell PT, Newton CC, Patel AV, et al. Diabetes and cause-specific mortality in a prospective cohort of one million U.S. adults. Diabetes Care. 2012; 35: 1835–44.

26. Esposito K, Chiodini P, Colao A, et al. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care. 2012; 35: 2402–11.

27. Hakim S, Bertucci MC, Conduit SE, et al. Inositol polyphosphate phosphatases in human disease. Curr Top Microbiol Immunol. 2012; 362: 247–314.

28. Currie CJ, Poole CD, Jenkins-Jones S, et al. Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care. 2012; 35: 299–304.

29. Kiderlen M, de Gas NA, Bastiaannet E, et al. Diabetes in relation to breast cancer relapse and all-cause mortality in elderly breast cancer patients: a FOCUS study analysis. Ann Oncol. 2013; 24: 3011–6.

30. Decensi A, Puntoni M, Goodwin P, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res. 2010; 3: 1451–61.

31. Kongara S, Karantz V. The interplay between autophagy and ROS in tumorigenesis. Front Oncol. 2012; 2: 171.

32. Hale G, Rebello P, Al Bakir I, et al. Pharmacokinetics and antibody responses to the CD3 antibody otelixizumab used in the treatment of type 1 diabetes. J Clin Pharmacol. 2010; 50: 1238–48.

33. Yamashita T. Glycosphingolipid modification: structural diversity, functional and mechanistic integration of diabetes. Diabetes Metab J. 2011; 35: 309–16.

34. Chavez JA, Summers SA. A ceramide-centric view of insulin resistance. Cell Metab. 2012; 15: 585–94.

35. Holland WL, Brozinick JT, Wang LP, et al. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metab. 2007; 5: 167–79.

36. Pagadala M, Kasumov T, McCullough AJ, et al. Role of ceramides in nonalcoholic fatty liver disease. Trends Endocrinol Metab. 2012; 23: 365–71.

37. Liang YJ, Ding Y, Lavery SB, et al. Differential expression profiles of glycosphingolipids in human breast cancer stem cells vs. cancer non-stem cells. Proc Natl Acad Sci USA. 2013; 110: 4968–73.

38. Handa K, Hakomori SI. Carbohydrate to carbohydrate interaction in development process and cancer progression. Glycocoen J. 2012; 29: 627–37.

39. Gupta V, Bhinge KN, Hosain SB, et al. Ceramide glycosylation by glucosylceramide synthase selectively maintains the properties of breast cancer stem cells. J Biol Chem. 2012; 287: 37195–205.

40. Hakomori SI. Structure and function of glycosphingolipids and sphingolipids: recollections and future trends. Biochim Biophys Acta. 2008; 1780: 325–46.

41. Liu YY, Patwardhan GA, Xie P, et al. Glucosylceramide synthase, a factor in modulating drug resistance, is overexpressed in metastatic breast carcinoma. Int J Oncol. 2011; 39: 425–31.

42. Hamacher-Brady A, Stein HA, Turschner S, et al. Artesunate activates mitochondrial apoptosis in breast cancer cells via iron-catalyzed lysosomal reactive oxygen species production. J Biol Chem. 2011; 286: 6587–601.

43. Samani AA, Yakar S, LeRoith D, et al. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev. 2007; 28: 20–47.

44. Kurmasheva RT, Houghton PJ. IGF-I-mediated survival pathways in normal and malignant cells. Biochim Biophys Acta. 2006; 1766: 1–22.

45. Ohtani M, Numazaki M, Yajima Y, et al. Mechanisms of antibody-mediated insulin-like growth factor I receptor (IGF-IR) down-regulation in MCF-7 breast cancer cells. BioScience Trends. 2009; 3: 131–8.

46. Awan MU, Deng Y. Role of autophagy and its significance in cellular homeostasis. Appl Microbiol Biotechnol. 2014; 98: 5319–28.

47. Cop M, Abdulkarim B, Bottu G, et al. RNA sequencing identifies dysregulation of the human pancreatic islet transcriptome by the saturated fatty acid palmitate. Diabetes. 2014; 63: 1978–93.

48. Liu JP. Molecular mechanisms of ageing and related diseases. Clin Exp Pharmacol Physiol. 2014; 41: 445–58.

49. Dieli-Conwright CM, Mortimer JE, Schroeder ET, et al. Randomized controlled trial to evaluate the effects of combined progressive exercise on metabolic syndrome in breast cancer survivors: rationale, design, and methods. BMC Cancer. 2014; 14: 238.

50. Gordon-Larsen P, Koehler E, Howard AG, et al. Eighteen year weight trajectories and metabolic markers of diabetes in modernising China. Diabetologia. 2014; 57: 1820–9.

51. Bachu E, Negri C, Tagari C, et al. Relationships between cardiorespiratory fitness, metabolic control, and fat distribution in type 2 diabetes subjects. Acta Diabetol. 2014; 51: 369–75.

52. Bettahi I, Sun H, Gao N, et al. Genome-wide transcriptional analysis of differentially expressed genes in diabetic, healing corneal epithelial cells: hyperglycemia-suppressed TGFbeta3 expression contributes to the delay of epithelial wound healing in diabetic cornneas. Diabetes. 2014; 63: 715–27.

53. Ruiz-Narvaez EA, Rosenberg L, Rotimi CN, et al. Genetic variants on chromosome 5p12 are associated with risk of breast cancer in African American women: the Black Women’s Health Study. Breast Cancer Res Treat. 2010; 123: 525–30.